Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction on April 28, 2026, regarding its partnership with TARA Mind. The original release had announced a collaboration to support Phase 3 recruitment for its HLP003 program in major depressive disorder and expand outreach in veteran communities. The correction removed references to Veterans Exploring Treatment Solutions from earlier paragraphs but reaffirmed the collaboration's alignment with a recent executive order aimed at advancing mental health treatments and clinical research participation.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is dedicated to developing proprietary novel serotonergic agonists (NSAs) designed to activate serotonin pathways believed to promote neuroplasticity. These synthetic molecules target large unmet needs in depression, anxiety, and other mental health conditions. The company's lead candidate, HLP003, is in Phase 3 clinical development for adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs.
The corrected partnership with TARA Mind underscores the company's commitment to advancing mental health treatments, particularly within veteran communities. The collaboration aims to facilitate recruitment for the HLP003 Phase 3 trial while supporting broader mental health initiatives. The correction clarifies the specific entities involved, ensuring accurate representation of the partnership's scope. This alignment with executive orders highlights the growing recognition of the need for innovative therapies and increased clinical trial participation among underserved populations.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company's website or follow on social media. The full press release can be viewed here. InvestorWire, a platform for advanced wire-grade press release syndication, distributed this announcement. InvestorWire is part of the Dynamic Brand Portfolio @IBN, offering services including access to a vast network of wire solutions, article syndication to over 5,000 outlets, and social media distribution.
